GeneThera, Inc. is a biotechnology company that focuses on eradicating zoonotic diseases such as COVID-19 (Novel Coronavirus), Paratuberculosis (Johne’s disease), Mad Cow Disease, Chronic Wasting Disease, and E.coli and Salmonella infections by applying proprietary molecular sciences and technologies. The company is headquartered in Westminster, Colorado and currently employs 2 full-time employees. The company went IPO on 2000-01-31. The firm is focused on developing genetics-based diagnostic assays and vaccine solutions and molecular diagnostic tests, therapeutics, and vaccines through its technologies for controlling the spread of zoonotic infection. The firm has developed a Molecular Robotic/AI Laboratory Platform (MORAP), which combine the use of advanced robotic laboratory systems integrated with artificial intelligence software systems. Its MORAPAT is designed to prevent the spread of disease from animals and control zoonotic infectious agents. The firm has also developed a large-scale process for highly purified and high viral titer (viral concentration) Adenovirus and Adeno-associated virus (AAV) genetically engineered viruses. This technology develops Adenovirus and AAV-based recombinant DNA vaccines for zoonotic pathogens. PURIVAX is a purification system that enhances biological purity and viral titer of recombinant Adenovirus and AAV vectors.